| Title: |
Favourable long-term outcomes in selected HER2-Positive early breast cancer patients without pathological complete response after neoadjuvant chemotherapy and trastuzumab: A pre–T-DM1 era cohort study |
| Authors: |
Doucet, Ludovic; Moreau-Bachelard, Camille; Mathiot, Laurent; Kerdraon, Olivier; Robert, Marie; Quintin, Julie; Bocquet, François; Zenatri, Morgan; Campone, Mario; Frenel, Jean-Sébastien |
| Contributors: |
Institut de Cancérologie de l'Ouest Angers/Nantes (UNICANCER/ICO); UNICANCER; Centre de Recherche en Cancérologie et Immunologie Intégrée Nantes-Angers (CRCI2NA); Université d'Angers (UA)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Nantes Université - UFR de Médecine et des Techniques Médicales (Nantes Univ - UFR MEDECINE); Nantes Université - pôle Santé; Nantes Université (Nantes Univ)-Nantes Université (Nantes Univ)-Nantes Université - pôle Santé; Nantes Université (Nantes Univ)-Nantes Université (Nantes Univ) |
| Source: |
ISSN: 2468-2942 ; Cancer Treatment and Research Communications ; https://nantes-universite.hal.science/hal-05459721 ; Cancer Treatment and Research Communications, 2026, 46, pp.101078. ⟨10.1016/j.ctarc.2025.101078⟩. |
| Publisher Information: |
CCSD; Elsevier, [2016]- |
| Publication Year: |
2026 |
| Collection: |
Université de Nantes: HAL-UNIV-NANTES |
| Subject Terms: |
Trastuzumab emtansine; Pathologic complete response; KATHERINE trial; HER2-positive early breast cancer; [SDV.MHEP]Life Sciences [q-bio]/Human health and pathology |
| Description: |
International audience ; Background: Adjuvant trastuzumab emtansine (T-DM1) is the standard treatment for HER2-positive early breast cancer (EBC) patients who do not achieve a pathologic complete response (pCR) after neoadjuvant chemotherapy (NAC). Given the heterogeneity within this population, we analyzed long-term outcomes in non-pCR HER2-positive EBC patients who received adjuvant trastuzumab prior to the availability of the KATHERINE trial results METHODS: This single-center cohort study included all HER2-positive EBC patients treated with neoadjuvant chemotherapy at our hospital between 2006 and 2017. Kaplan-Meier and multivariable Cox regression models were employed to assess long-term invasive disease-free survival (iDFS) and overall survival (OS).Results: This study included 103 patients, of which 67.0 % had a residual tumor size of ypT1, and 57.3 % had no residual tumor in the lymph nodes. The median follow-up was 9.3 years. At 3, 5, and 7 years, the iDFS rates were 78.3 %, 72.2 %, and 69.7 %, and the overall survival rates were 90.2 %, 83.3 %, and 79.8 %, respectively. Multivariate analysis identified ypT |
| Document Type: |
article in journal/newspaper |
| Language: |
English |
| Relation: |
info:eu-repo/semantics/altIdentifier/pmid/41496262; PUBMED: 41496262 |
| DOI: |
10.1016/j.ctarc.2025.101078 |
| Availability: |
https://nantes-universite.hal.science/hal-05459721; https://nantes-universite.hal.science/hal-05459721v1/document; https://nantes-universite.hal.science/hal-05459721v1/file/1-s2.0-S246829422500214X-main.pdf; https://doi.org/10.1016/j.ctarc.2025.101078 |
| Rights: |
http://creativecommons.org/licenses/by-nc-nd/ ; info:eu-repo/semantics/OpenAccess |
| Accession Number: |
edsbas.D3B1A9D9 |
| Database: |
BASE |